PubRank

H Allgayer

Author PubWeight™ 43.89‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene 2007 10.79
2 Regulation of Axl receptor tyrosine kinase expression by miR-34a and miR-199a/b in solid cancer. Oncogene 2011 1.75
3 Tumor suppressor Pdcd4 inhibits invasion/intravasation and regulates urokinase receptor (u-PAR) gene expression via Sp-transcription factors. Oncogene 2007 1.62
4 MicroRNA-520/373 family functions as a tumor suppressor in estrogen receptor negative breast cancer by targeting NF-κB and TGF-β signaling pathways. Oncogene 2011 1.57
5 Is radical scavenging necessary in the treatment of inflammatory bowel disease? Gastroenterology 1991 1.39
6 Individual development and uPA-receptor expression of disseminated tumour cells in bone marrow: a reference to early systemic disease in solid cancer. Nat Med 1995 1.30
7 Gene expression profiling of liver metastases and tumour invasion in pancreatic cancer using an orthotopic SCID mouse model. Br J Cancer 2007 1.23
8 Effects of antacids on the clinical pharmacokinetics of drugs. An update. Clin Pharmacokinet 1990 1.23
9 QuickMap: a public tool for large-scale gene therapy vector insertion site mapping and analysis. Gene Ther 2009 1.11
10 Downregulation of E-cadherin is an essential event in activating beta-catenin/Tcf-dependent transcription and expression of its target genes in Pdcd4 knockdown cells. Oncogene 2009 1.03
11 Tumor-associated proteolysis and prognosis: new functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system. J Clin Oncol 1995 0.97
12 Identification of a novel nuclear factor-kappaB sequence involved in expression of urokinase-type plasminogen activator receptor. Eur J Biochem 2000 0.96
13 Drug-induced fibrosing colonopathy in inflammatory bowel disease after 5-ASA? Dig Dis Sci 1999 0.95
14 Clinical value of extended biologic staging by bone marrow micrometastases and tumor-associated proteases in gastric cancer. Ann Surg 1997 0.91
15 Influence of autologous blood transfusion on natural killer and lymphokine-activated killer cell activities in cancer surgery. Vox Sang 1997 0.90
16 Prognostic influence of blood transfusion on minimal residual disease in resected gastric cancer patients. Anticancer Res 1997 0.89
17 Effect of olsalazine and mesalazine on human ileal and colonic (Na+ + K+)-ATPase. A possible diarrhogenic factor? Clin Investig 1993 0.89
18 A region between -141 and -61 bp containing a proximal AP-1 is essential for constitutive expression of urokinase-type plasminogen activator receptor. Eur J Biochem 1999 0.89
19 Modulation of immune response by blood transfusion: evidence for a differential effect of allogeneic and autologous blood in colorectal cancer surgery. Shock 1997 0.83
20 Enzastaurin inhibits invasion and metastasis in lung cancer by diverse molecules. Br J Cancer 2010 0.83
21 Perisurgical erythropoietin application in anemic patients with colorectal cancer: A double-blind randomized study. Surgery 1996 0.82
22 Soybean lipoxygenase inhibition: studies with the sulphasalazine metabolites N-acetylaminosalicylic acid, 5-aminosalicylic acid and sulphapyridine. Eur J Clin Pharmacol 1984 0.80
23 Analysis of self-inactivating lentiviral vector integration sites and flanking gene expression in human peripheral blood progenitor cells after alkylator chemotherapy. Hum Gene Ther 2010 0.80
24 Stimulation of urokinase-type plasminogen activator receptor expression by PMA requires JNK1-dependent and -independent signaling modules. Oncogene 1998 0.80
25 Multiple displacement amplification enables large-scale clonal analysis following retroviral gene therapy. J Virol 2007 0.79
26 The prognostic impact of the urokinase-type plasminogen activator system is associated with tumour differentiation in gastric cancer. Eur J Surg Oncol 1996 0.79
27 Effect of short-term topical corticosteroid treatment on mucosal enzyme systems in patients with distal inflammatory bowel disease. Hepatogastroenterology 1999 0.79
28 Ras regulation of urokinase-type plasminogen activator. Methods Enzymol 2001 0.79
29 Identification of an histone H3 acetylated/K4-methylated-bound intragenic enhancer regulatory for urokinase receptor expression. Oncogene 2006 0.79
30 Increased dose-response relationship of liver plasma membrane adenylate cyclase to glucagon stimulation in diabetic rats. A possible role of the guanyl nucleotide-binding regulatory protein. Diabetologia 1982 0.78
31 [Mebendazole therapy in echinococcosis. Long-term study and course parameters in 8 patients]. Dtsch Med Wochenschr 1984 0.78
32 F2A sequence linking MGMT(P140K) and MDR1 in a bicistronic lentiviral vector enables efficient chemoprotection of haematopoietic stem cells. Cancer Gene Ther 2012 0.78
33 [Insulin, glucagon binding and adenylate cyclase activity of liver plasma membranes in streptozotocin-diabetic rats]. Verh Dtsch Ges Inn Med 1978 0.77
34 Less advanced stages of colon cancer in patients with type 2 diabetes mellitus: an unexpected finding? Exp Clin Endocrinol Diabetes 2012 0.76
35 A real time PCR based approach for the quantitative detection of FUS-CHOP fusion transcripts in human liposarcoma. Adv Med Sci 2012 0.75
36 Different iron-chelating properties of aminosalicylates. Gastroenterology 1992 0.75
37 Studies on the in vitro interaction of D-penicillamine with antacids. Arzneimittelforschung 1983 0.75
38 [The glucagon-dependent stimulation of cyclic AMP--a new diagnostic liver test?]. Z Gastroenterol 1983 0.75
39 Inhibition of human colonic (Na+ + K+)-ATPase by arachidonic and linoleic acid. Naunyn Schmiedebergs Arch Pharmacol 1986 0.75
40 Absence of in vivo and in vitro interactions of an aluminum hydroxide, magnesium hydroxide containing antacid with cimetidine in patients with peptic ulcer. Z Gastroenterol 1983 0.75
41 COX-2, TFF1, and Src define better prognosis in young patients with gastric cancer. J Surg Oncol 2013 0.75
42 Can cyclosporin prevent proctocolectomy in severe steroid-refractory ulcerative colitis? Lessons from a case report. Dig Dis Sci 1993 0.75
43 [Acute epigastric disorders and recurring thrombophlebitis]. Internist (Berl) 1983 0.75
44 [Salazosulfapyridine: old and new therapy concepts in inflammatory bowel diseases]. Dtsch Med Wochenschr 1985 0.75
45 [2 patients with melena and hematochezia of undetermined origin]. Internist (Berl) 1985 0.75
46 Determination of the pK values of 5-aminosalicylic acid and N-acetylaminosalicylic acid and comparison of the pH dependent lipid-water partition coefficients of sulphasalazine and its metabolites. Arzneimittelforschung 1985 0.75
47 [A patient with cavernous lung foci, arthralgias and eye symptoms]. Internist (Berl) 1983 0.75
48 Salicylate and diarrhea. Gastroenterology 1987 0.75
49 Pneumoperitoneum following colonoscopy in a patient with a solitary rectal ulcer. Endoscopy 1991 0.75
50 Studies on the in vitro binding of D-penicillamine to cholestyramine. Experientia 1982 0.75
51 Olsalazine-related diarrhoea: does rat intestine adapt in vivo? Scand J Gastroenterol 1992 0.75
52 Lack of effect of haemodialysis on mebendazole kinetics: studies in a patient with echinococcosis and renal failure. Eur J Clin Pharmacol 1984 0.75
53 Comparative pharmacokinetics of sulphasalazine and sulphapyridine after rectal and oral administration to patients with ulcerative colitis. Eur J Clin Pharmacol 1984 0.75
54 Studies on the in vitro interactions of cimetidine with commercial antacid preparations and chemically pure components. Arzneimittelforschung 1984 0.75